Screener
Hemab Therapeutics Holdings, Inc. COAG Accrued Contract Research And Development Costs
Accrued Contract Research And Development Costs at other companies
Other financials
Where this comes from
Reported directly by Hemab Therapeutics Holdings, Inc. in its filing.
Tagged under the XBRL concept coag:AccruedContractResearchAndDevelopmentCosts.
The source filing: Hemab Therapeutics Holdings, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344533
FAQ
- What is Hemab Therapeutics Holdings, Inc.'s accrued contract research and development costs?
- Hemab Therapeutics Holdings, Inc. (COAG) reported accrued contract research and development costs of $2.75M in Q2 2026.
- What does accrued contract research and development costs mean?
- Accrued Contract Research And Development Costs as reported by Hemab Therapeutics Holdings, Inc. Common Stock.
Ask your AI about Hemab Therapeutics Holdings, Inc.'s accrued contract research and development costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude